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Introduction
Gene expression regulation through epigenetic factors is a
concept that is well established nowadays. It is defined as a
pattern of changes in gene expression without altering the un-
derlying DNA sequence.[1] Living cells must be able to dynami-
cally respond to changes in physiological and environmental
stimuli and to modify their chromatin structure accordingly. A
complex set of regulatory events, for example, DNA modifica-
tion by cytosine methylation or covalent histone modifications
have been shown to alter the interactions between DNA and
histones. Modifications promote either compaction or relaxa-
tion of the chromatin, and thus, play a direct role in controlling
the transcription level of particular genes. Epigenetic control
occurs in both healthy and cancerous cells.[2] For instance,
aberrant histone modification exhibits a clear relationship with
disease and is often associated with cancer.[3] The ability to in-
terfere with these processes is therefore of increasing interest
for researchers from the academic sector and from pharma-
ceutical companies.
One of the most studied histone modifications is the addi-
tion of a methyl group to lysine residues, as a result of the
action of histone lysine methyltransferase enzymes (KMTs).[4]
The histone tails, which are packed more loosely than the his-
tone cores, have been identified as the main targets for modifi-
cations by KMTs.[5] Despite the subtle physicochemical effect of
lysine methylation, it has a tremendous regulatory impact on
cellular functions. Combining the number of lysine residues in
histones, which can be methylated, the various degrees of
methylation (mono-, di-, and trimethylation), and the fact that
methylation is cooperative with other modifications results in a
very complex picture for gene expression control.[6] Until about
2004, histone lysine methylation was believed to be irreversi-
ble. Since then, two classes of reverse-action (eraser) en-
zymes—histone lysine demethylases—have been discovered
and studied in depth. Usually, these enzymes are selective for
a particular lysine residue in a particular methylated state. The
first class comprises the flavin-dependent lysine-specific deme-
thylases (LSDs or KDM1s). The second class, which has more
members than the first, comprises all oxygen-dependent de-
methylases, which use iron(II) and 2-oxoglutarate (2OG, also
called a-ketoglutarate) as cofactors. The enzymes, which
Human histone demethylases are known to play an important
role in the development of several tumor types. Consequently,
they have emerged as important medical targets for the treat-
ment of human cancer. Herein, structural studies on tetrazolyl-
hydrazide inhibitors as a new scaffold for a certain class of his-
tone demethylases, the JmjC proteins, are reported. A series of
compounds are structurally described and their respective
binding modes to the KDM4D protein, which serves as a high-
resolution model to represent the KDM4 subfamily in crystallo-
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target-binding affinity and increased membrane permeability,
at the same time.
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belong to the second class, contain the Jumonji domains;
hence, they are also called JmjC KDMs.[7] The discovery of
these enzymes established an entirely new concept, with re-
spect to the dynamic reversible regulation of histone methyla-
tion by KMTs and KDMs.
In humans, the JmjC histone lysine demethylases encompass
distinct families, each of which consist of several multidomain
members. There are at least six KDM families recognized in the
literature (KDM2–7) and still new subfamilies (KDM8 and
KDM9) are being reported. The catalytic function of these en-
zymes is provided by the JmjC domain, whereas the JmjN
domain closely interacts with JmjC and provides the three-di-
mensional scaffold. All members are classified based on the
presence of conserved structural elements, in addition to the
catalytic JmjC domain, including PHD, Tudor, CXXC, FBOX,
ARID, LRR, and JmjN domains.[7, 8]
The five members of the KDM4 subfamily (KDM4A–E) cata-
lyze the removal of the methyl group from tri- and dimethylat-
ed lysine residue 9 in histone 3 (H3K9me3/me2). At the same
time, KDM4A–C also process the tri- and dimethylated lysine
residue 36 (H3K36me3/me2). Increasing evidence has been ac-
cumulated that KDMs are also linked with various disease
states.[9] For instance, KDM4B was found to be involved in
breast, colon, and gastric cancer,[10] whereas KDM4A, KDM4C,
and KDM4D are overexpressed in prostate cancer, during
which they act as androgen receptor coactivators.[11] Conse-
quently, these enzymes have been identified as potential tar-
gets for intervention by drugs. At present, four compounds tar-
geting LSD1 are in clinical trials, whereas for the JmjC KDM
family of enzymes no such developments have been report-
ed.[12]
In spite of this, a large number of small-molecule inhibitors
of JmjC KDMs have been established. For the KDM4 subfamily
alone, about 94 structures with bound ligands[13] have been
deposited in the Protein Data Bank (PDB).[14] Most of the inhibi-
tors are 2OG competitors that coordinate the Fe2+ ion in the
catalytic center and sometimes penetrate into the histone pep-
tide binding pocket. Many of these compounds mimic the nat-
ural cofactor and, similar to 2OG, possess a carboxylic acid
moiety. The carboxylic group is a common building block in
endogenous substances, but it is also part of many pharmaco-
phores.[15] Its success is due to its acidic character and potential
to engage in relatively strong electrostatic interactions and hy-
drogen bonds. On the other hand, the carboxylic moiety re-
duces the ability of a drug to passively move across biological
membranes, and thus, limits cell permeability. Two different
strategies are suited to overcoming this problem associated
with drugs and drug candidates: 1) bioisosteric replacement or
2) prodrug strategies, such as use of carboxylic acid esters.
Consequently, in a drug development process of carboxylic
acid leads against JmjC KDMs, several ester compounds have
been investigated.[16] Because this well-established strategy po-
tentially yields prodrugs that are transformed into the active
form differently in individual patients, the replacement of the
carboxylic acid by groups with similar volume, shape, and
physicochemical properties is an attractive alternative. From
this perspective, it is quite surprising that structural data for
KDM4 proteins and compounds containing tetrazole moieties
have not been reported, although the tetrazole moiety is part
of many biologically active compounds, including drugs.[17] Al-
though the electrostatic potentials of carboxyl and tetrazole
groups are similar, tetrazoles could improve the cellular perme-
ability due to their more lipophilic character. Tetrazoles are
low-toxic, metabolically stable bioisosteres of carboxylic acids,
and thus, promising building blocks for analogues of the natu-
ral KDM4 cofactor, 2OG.[18] However, none of the KDM4–ligand
complexes reported so far in the PDB contain a tetrazole ring
as a functional group.
In 2015, Reger et al. identified tetrazolylhydrazides as selec-
tive fragment-like inhibitors of the KDM4 subfamily of pro-
teins.[19] Arrays of such molecules have since been synthesized
and analyzed mainly by molecular modeling approaches.[20]
The most promising compounds suggested a mode of binding
in the KDM4 active site. The assumption was that the tetrazole
group acted through binding to the 2OG site as a competitor
for the substrate. However, direct support for this hypothesis
by experimental structural analysis has so far been lacking.
Herein, we present the first successful attempt to obtain
high-resolution X-ray structures of both hydrazide and tetra-
zole moieties bound to the enzyme KDM4D. These small mole-
cules constitute promising frameworks for early drug discovery
stages because their initial selectivity has been reported.[19] The
structures presented herein show the specific binding of tetra-
zolylhydrazide ligands[19,20] (Figure 1) to the metal ion in the
Figure 1. Structures of compounds 1 to 7, which have been cocrystallized with KDM4D.
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active site, serving as 2OG competitors. A series of molecules
with hydrazide and tetrazole ring modifications show different
modes of binding in the active center of the enzyme. Mapping
of the active site allowed us to localize the residues that were
able to adjust their position upon ligand binding. Our attempt
to describe compounds that exclusively inhibit this relatively
new target KDM4 has resulted in structural data that show the
mode of binding of new functional groups that have not been
described previously : tetrazole and hydrazide. Uncovering and
describing these details is a step forward in the development
of drug-like molecules in the fight against cancer.
Results
KDM4D crystals and KDM4D structure
All structural work reported herein was performed on the cata-
lytic core of KDM4D, which comprised amino acid residues 1–
342. This construct crystallizes in a form that renders the active
site of the protein fully accessible, with no obstructions from
neighboring protein molecules in the crystal lattice. In all
KDM4 subfamily members, the 2OG binding site is literally the
same and engages the same residues. The tetragonal crystal
form features one molecule in the asymmetric unit and per-
mits the diffusion of ligand molecules through the solvent
channels to the substrate binding pocket of the protein. This
crystal form of KDM4D has been observed previously (PDB ID:
3DXU, unpublished), and based on our own observations, it
turned out to be superior to others for ligand soaking experi-
ments due to its diffraction properties, mechanical stability,
and tolerance for high DMSO concentrations. In all obtained
structures, the part of the amino acid sequence that was visi-
ble in the electron density included residues 11–342. Overall,
the structure of KDM4D is globular and may be divided into
the JmjN and JmjC domains. The N-terminal JmjN domain
comprises residues 18–60 and the catalytic JmjC domain com-
prises residues 146–312 (Figure 2). These domains are highly
similar to the homologous domains of other KDM4 proteins.
As in other KDM4 subfamily members, a conserved zinc-bind-
ing site composed by the residues His244, Cys238, Cys310, and
Cys312 was observed. This binding site is of mainly structural
importance. The Zn2+ ion is present with 100% occupancy
and has its origin in the Escherichia coli host organism because
no Zn2+ was added to any of the purification or crystallization
buffers. The active-site metal center contains Ni2+ as the metal
ion. Although in the natural form of the enzyme this site is oc-
cupied by an Fe2+ ion, it is widely accepted in crystallographic
studies to replace rather oxygen-sensitive Fe2+ with Ni2+ or
Co2+ . All of the ligands (1–7; Figure 1) reported in this study
occupy the native cofactor binding site, which is in close vicini-
ty to the metal binding site and the site binding the methylat-
ed histone lysine. Based on available statistics (Table 2) and the
quality of experimental data, the structures reported herein are
of sufficiently high quality to ascertain the binding of the
soaked-in ligands. The entire catalytic core and the binding of
the cofactor 2OG and a trimethylated peptide that mimics the
histone 3 tail (H3K9me3) has been thoroughly described by
Figure 2. Structure and ligand binding of demethylase KDM4D. Top: Domain
organization in KDM4D. The colors are in accordance with the secondary
structure representation. Middle: The core domain of KDM4D in ribbon rep-
resentation. The JmjN domain is colored in blue and the JmjC domain in
orange. Ligand 1 structure and superimposed elements from the reported
structure (PDB ID: 4HON[13m])—cofactor 2OG and the “incoming” trimethylat-
ed lysine (Kme3, part of the histone like peptide)—can be seen in the
active-site pocket. Superposition of ligand 1 with the 2OG-bound structure
shows high structural similarities between bioisosteres. Substrate binding
site residues with semitransparent secondary structure elements can be visi-
ble. The cofactor and trimethylated lysine residue are given in ball-and-stick
representation in magenta, whereas the tetrazolehydrazide ligand and bind-
ing residues are in yellow. Bottom: Surface representation of KDM4D with
the ligand in the binding pocket and the histone-like peptide bound on the
surface is superimposed in magenta as stick representation.
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Krishnan and Trievel.[13m] Cofactor 2OG chelates the active-site
Ni2+ ion by using both the C2 keto group and C1 carboxylate
group. In addition, the octahedral coordination sphere of the
metal center contains Gln194, which binds opposite to the C2
keto group; His192, which binds opposite to the C1 carboxyl-
ate group; His280; and a water molecule. The other end of co-
factor 2OG is held in place by Asn202, Lys210, and Tyr136
(Figure 2). The active-site residues Tyr181, Glu194, and Gly174
are in close vicinity around the trimethylated lysine of the his-
tone.[13m] The peptidic ligand was not used in our experiments;
thus, it is not observed in the structures reported herein, but
superimposed in Figure 2 for visualization of the histone bind-
ing site in KDM4 proteins.
Ligand binding examined by crystal structure analysis
Compounds 1–7, which all contain a tetrazole group (Figure 1),
were individually soaked into KDM4D crystals. This resulted in
a series of seven crystal structures of KDM4D ligand complexes
(Figure 3). The full picture of spatial positioning and detailed
web of interactions of protein residues with compounds are
discussed in the following subsections. All structures are of
high quality, as evidenced by their resolution and refinement
statistics (Tables 1 and 2). Although some ligands exhibit less
than 100% occupancy, which means that they are only bound
to a fraction of the protein molecules, their clear appearance
in the difference electron density map allows their unambigu-
ous placement in the structure. All compounds in this series,
except for compounds 4 and 5, are composed of two building
blocks intended as interaction motifs : the tetrazole ring and
the hydrazide group. Ligands mainly differ in the alternations
and modifications incorporated between them. The functional
groups of the compounds were designed with binding to the
KDM4 proteins through these two functional groups in mind.
In addition to compounds 1–5, which exhibit simple binding
motifs and some modifications, two more complicated tetrazo-
lylbenzohydrazide compounds (compounds 6 and 7) were in-
vestigated. In these compounds, the tetrazole ring is attached
in meta and para positions to the benzene ring.
Structure of KDM4D with compound 1
The lead structure, compound 1, represents the molecule with
the shortest distance between the two interaction motifs : only
one methylene group separates the tetrazole group and the
hydrazide (n=1). In the structure of compound 1 bound to
KDM4D, a clear positive difference electron density for the
ligand could be observed and the ligand could be modeled
with 77% occupancy (Figure 3A). Its hydrazide group chelates
to the active site Ni2+ , which is a surrogate of iron, as dis-
cussed above. The mode of chelation is very similar to that ob-
served in the binding of the natural 2OG cofactor (Fig-
ure 2).[13m] The aromatic tetrazole ring is sandwiched between
the two active-site aromatic residues Phe189 and Tyr181. The
distances between the tetrazole and the centers of the aromat-
ic rings are 4.2 and 4.9 a for Phe189 and Tyr181, respectively;
thus indicating an aromatic stacking interaction. The distance
of 2.6 a between the hydroxy of Tyr136 and the second nitro-
gen atom from the tetrazole ring indicates strong hydrogen
bonding. All of the other nitrogen atoms in the tetrazole ring
are connected to the protein residues through clearly defined
water molecules.
Structure of KDM4D with compound 2
Compound 2 is characterized by two methylene groups be-
tween the functional groups (n=2). In the complex structure
with KDM4D, this leads to a shift of the tetrazole ring relative
to its position in the complex with compound 1, whereas the
hydrazide group remains unchanged (Figure 3B). The observed
electron density for the side chain of Tyr136 reveals that its po-
sition has changed. In its major conformation (64% occupan-
cy), the side chain has moved by 3.6 a relative to its position
in the structure with shorter compound 1. The first nitrogen
atom of the tetrazole ring interacts with Tyr136-OH at a dis-
tance of 2.7 a and the third nitrogen atom with Lys210-NZ at a
distance of 2.8 a. The aromatic stacking interactions are still
present, with distances between the centers of the aromatic
rings of 4.3 and 4.6 a for Phe189 and Tyr181, respectively.
Structure of KDM4D with compound 3
In the case of an even longer ligand with n=3 (3), the hydra-
zide group remains in the same position as those reported for
both n=1 and 2. The tetrazole ring still interacts with Lys210-
NZ, but it is shifted by about 1.8 a away from the position ob-
served in the case of compound 1. It is now located at the po-
sition of Tyr136, and thus, forces the tyrosine aromatic ring fur-
ther away, so that the residue–ligand interaction is no longer
observed (Figure 3C).
Structure of KDM4D with compound 4
Compound 4 is characterized by the substitution of the hydra-
zide with an ester group. It could be modeled with clear elec-
tron density in the binding groove. Its tetrazole group is coor-
dinated by two residues, Lys245 and Tyr136. Lys245-NZ, the
electron density of which usually identifies two distinct confor-
mations, is clearly defined and pointing inward into the active
site (Figure 3D). The two remaining nitrogen atoms of the tet-
razole are hydrogen bonded to water molecules and through
one water molecule to the active-site metal ion. The orienta-
tion of the ligand is flipped by 1808 around the tetrazole ring
relative to the orientation observed for compounds 1 and 2.
The position of the tetrazole ring is 1.4 a away from the tetra-
zole in the case of ligand 1. The ester tail of the ligand spans
the binding cavity at its entrance, close to the surface of the
protein, forming hydrophobic interactions with the protein.
Structure of KDM4D with compound 5
Compound 5 is a variant of compound 1 with a methyl sub-
stituent at position 1 of the heterocyclic ring. The hydrazide
group of the ligand is placed in the same position as that in all
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structures described so far and it chelates the active-site metal
ion. However, the whole decorated tetrazole group is turned
by 858, and its carbon atom points toward Tyr181, whereas the
ring is placed between Asn202 and Lys210 (Figure 3E). The
third nitrogen atom of the ring binds to a water molecule
through a hydrogen bond.
Structure of KDM4D with compound 6
Compound 6 has a tetrazole ring in the para position of the
benzene ring. The benzene ring is placed 4.4 a away from
Phe189 and 5.4 a away from Tyr181. The second nitrogen
atom of the tetrazole ring is hydrogen bonded to Asn284-N
Figure 3. Details of the interaction of the seven ligands with KDM4D. The protein part of the structure is depicted as ribbons, except for the side chains of
the relevant amino acid residues, which are shown as sticks. The presence of the ligand, also depicted as sticks, is evidenced by the (2mFo-DFc, ac)-composite
omit map in green contoured at 1.5s for compounds 1 (A), 2 (B), 4 (D), 5 (E), and 7 (G) ; at 1.1s for compound 3 (C) ; and at 0.8s for compound 6 (F). Water
molecules are shown as red spheres and the metal ion as a gray sphere. Polar interactions between the ligand and the protein, water molecules, and metal
ion are indicated as black dashed lines. The orange dashed lines highlight aromatic stacking interactions.
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and is oriented parallel to Tyr136 (Figure 3F). Compared with
all compounds analyzed previously, the hydrazide group is ro-
tated by 908. The nitrogen atom adjacent to the carbonyl
group occupies the position of a water molecule, which is
bound to the metal ion in previous cases, while the water mol-
ecule is now modeled in a position occupied by the nitrogen
atom of the hydrazide group in other cases.
Structure of KDM4D with compound 7
Compound 7 carries the tetrazole ring in the meta position of
the benzene ring. The hydrazide group binds in the same way
as that observed in all other structures (Figure 3G). The ben-
zene ring is positioned between both functional groups and is
engaged in stacking interactions with Tyr161 and Phe189 at
distances of 4.3 and 5.1 a, respectively. The first tetrazole nitro-
gen atom hydrogen bonds with Lys210 (2.9 a) and the second
nitrogen atom with Asn284 (3.1 a). The position of the ring is
only 0.8 a further away compared with the most similar ligand,
compound 3. Also, the aliphatic chain that links the tetrazole
and hydrazide groups in compound 3 ligand is found at the
same position as that of the benzene group of this ligand.
Ligand binding investigation
Isothermal titration calorimetry (ITC)
The affinity and energetics of the binding of tetrazole ligands
to KDM4D were studied by means of ITC. In all cases, the
ligand was titrated into the solution of protein in the calorime-
ter cell. The binding of compound 1 to KDM4D is exothermic
and characterized by a dissociation constant, Kd, of 2.3 mm. Al-
Table 1. Data collection and processing statistics. The values in parentheses are for the respective highest resolution shell.
1 2 3 4 5 6 7
beamline BL14.3 BL14.1 BL14.1 BL14.3 BL14.1 BL14.1 BL14.1
l [a] 0.8943 0.9184 0.9184 0.8943 0.9184 0.9184 0.9184
crystal–detector dis-
tance [mm]
120.1 180.8 210.0 120.1 196.9 196.7 180.6
resolution range [a] 48.01–1.33 (1.41–
1.33)
47.99–1.18 (1.22–
1.18)
48.04–1.35 (1.43–
1.35)
47.9–1.26 (1.33–
1.26)
47.92–1.47 (1.56–
1.47)
48.17–1.28 (1.36–
1.28)
48.24–1.33 (1.38–
1.33)
space group P43212 P43212 P43212 P43212 P43212 P43212 P43212
unit cell a, c [a] 71.63, 150.77 71.49, 150.44 71.67, 150.66 71.45, 150.54 71.46, 151.07 71.85, 151.53 72.00, 150.87
total no. reflections 687453 (108567) 1671018
(255958)
1122708
(179953)
1069690
(167899)
587371 (93159) 890260 (143199) 1187218
(177815)
no. unique reflections 168562 (27166) 247119 (39529) 165316 (26447) 202280 (32624) 127491 (20523) 195540 (31550) 174441 (28048)
multiplicity 4.1 6.8 6.8 5.3 4.6 4.6 6.8
completeness [%] 98.5 (98.6) 99.8 (98.7) 99.6 (98.3) 99.9 (99.6) 99.8 (99.3) 99.8 (99.3) 99.7 (99.2)
mean I/s(I) 15.4 (1.8) 16.0 (2.0) 16.4 (1.8) 16.5 (2.0) 18.2 (2.0) 16.9 (1.9) 20.1 (2.4)
Rmeas [%] 6.7 (86.9) 7.2 (95.5) 7.7 (103.4) 6.7 (92.9) 4.9 (78.7) 5.5 (85.3) 5.9 (79.9)
CC1/2 0.999 (0.613) 0.999 (0.694) 0.999 (0.676) 0.999 (0.679) 0.999 (0.685) 0.999 (0.636) 1.0 (0.77)
Wilson B factor (a2) 11.5 11.0 13.5 11.3 18.1 13.0 13.0
Table 2. Refinement and validation statistics.
1 2 3 4 5 6 7
refinement program Refmac5 and Phenix.refine
resolution 48.01–1.33 47.92–1.18 48.04–1.35 47.9–1.26 47.92–1.47 48.17–1.28 48.24–1.33
reflections in working set 166462 244532 163219 200134 125406 193437 172341
reflections in test set 2086 2582 2090 2117 2081 2099 2117
Rwork [%] 12.9 12.1 12.8 12.3 12.8 12.4 12.3
Rfree [%] 15.6 15.0 15.9 14.6 15.3 15.8 15.4
no. non-H atoms 3498 3646 3488 3530 3329 3495 3583
macromolecule 2957 3073 2970 2951 2914 2948 3043
ligands 65 79 47 78 52 70 44
water 459 474 452 486 351 464 478
RMS (bonds) [a] 0.035 0.024 0.028 0.013 0.031 0.009 0.028
RMS (angles) [8] 2.6 2.2 2.3 1.6 2.4 1.4 2.3
Ramachandran favored [%] 99 99 99 99 98 99 99
clashscore 7.12 5.50 7.13 1.98 4.92 3.66 9.69
average B factor [a2] 17.6 17.5 20.0 18.4 25.5 20.6 20.1
macromolecule 15.0 14.8 17.6 15.5 23.1 17.8 17.5
ligands 28.7 26.5 34.2 30.2 43.2 35.2 25.7
water 31.9 32.3 33.7 33.5 41.5 35.6 35.6
ligand occupancy 0.77 0.84 0.86 1 0.9 0.64 0.77
PDB ID 6ETS 6ETV 6ETW 6ETT 6ETE 6ETG 6ETU
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though the interaction is favored by both enthalpic (DH=
@2.6 kcalmol@1) and entropic (@TDS=@4.9 kcalmol@1) contri-
butions, the entropic part dominates and has a nearly twofold
higher impact on the Gibbs free energy of binding (DG=
@7.5 kcalmol@1; Table 3). Compound 2 displayed a rather large
differential power signal, but this signal could not be attribut-
ed to binding. It most likely originated from side effects of the
system, such as ligand dilution. No binding isotherms could be
observed for compounds 3–6. The binding of compound 7 to
KDM4D was found to be endothermic. With Kd=41 mm, it is
weaker, relative to the binding of compound 1. This interaction
is characterized by an unfavorable positive binding enthalpy
(DH=4.0 kcalmol@1), which is overcompensated for by the
rather strong entropic contribution (@TDS=@9.9 kcalmol@1).
In vitro KDM4A inhibition assays
Ligands 1–5 were previously tested by us in a fragment-based
screening against the closely related isozyme KDM4A. In brief,
ligand 1 was the most potent compound, with an IC50 value of
46.64:0.94 mm in a formaldehyde dehydrogenase (FDH)-cou-
pled assay. In the antibody-based LANCE Ultra assay, the po-
tency was as high as 2.38:0.37 mm. The two control com-
pounds, 4 and 5, in which one structural motif required for
potent binding (hydrazide or tetrazole) is replaced or masked,
exhibit no inhibition.[19] The two derivatives 6 and 7, with an
aromatic spacer, were characterized as noninhibiting. Apparent
IC50 values from both in vitro assays are reported in Table 4.
The apparent potency is much higher in the FDH-coupled
assay than that in the LANCE Ultra assay, which is in contrast
to previous observations for this and other structural classes of
inhibitors.[21] These results indicate an assay artifact in the FDH
assay. Indeed, a counterscreening assay revealed that com-
pounds 6 and 7 also negatively influenced the conversion of
formaldehyde by FDH in a KDM4A-free setup, potentially by di-
rectly inhibiting FDH, by reacting with released formaldehyde,
or by quenching the fluorescence signal (see Figure S1 in the
Supporting Information). As such, the results from the orthog-
onal LANCE Ultra assay appear to be more reliable; this means
that compounds 6 and 7 are, at best, very weak KDM inhibi-
tors. This is in agreement with the much less favorable binding
properties observed in the ITC measurements (Table 3).
Discussion
The aim of this work was to investigate the mode of binding
of the histone demethylase KDM4D in complex with tetrazolyl-
hydrazide compounds. Structural data describe, in detail, the
interactions of this molecular scaffold with the KDM4 cofactor
binding site and might be very helpful in the further develop-
ment of inhibitors of the KDM4 subfamily. In our opinion, the
most desired compounds should exhibit high affinity to make
them potent binders and, at the same time, they should pos-
sess physicochemical properties that would allow them to pen-
etrate cells across membranes. Only the combination of the
two properties in one compound would identify a compound
as one displaying high anti-KDM4 activity in vivo. To the best
of our knowledge, there is a limited number of KDM4 binding
compounds, to date, that feature both properties[13b] and tetra-
zolylhydrazides might fill this gap.
Role of the carboxyl group in KDM4 inhibitors
Early developed analogues of 2OG usually contain either one
or two carboxyl groups, for example, N-oxalylglycine (NOG;
PDB ID: 4D6S, unpublished) or 2,4-pyridinedicarboxylic acid
(2,4-PDCA; PDB ID: 4D6Q, unpublished; Figures 4A, C). In all
cases, one of the carboxylic groups is positioned in the same
way as that in the naturally occurring cofactor, 2OG. Other
scaffolds, which contain one carboxylic group, are, for instance,
2,2-bipyridines[13d] (PDB ID: 3PDQ), 8-hydroxyquinoline (8HQ,
PDB ID: 4BIS), and derivatives of 8HQ[13i] (8-hydroxy-3-(pipera-
zin-1-yl)quinoline-5-carboxylic acid; PDB ID: 3RVH; Figure 4D–
F). Several attempts were made to enhance the cell permeabili-
ty of such KDM4 binding molecules. For instance, ester modifi-
cations were introduced to produce a prodrug, for example, in
the case of MethylStat, which is a pan-KDM inhibitor.[22] Howev-
er, it has been reported repeatedly that the carboxyl group
was needed to maintain the potency of the inhibitor mole-
cules. This can easily be explained by examining the interac-
tions of the carboxyl groups with the enzyme, which are high-
lighted in several crystal structures of KDM4 complexes with li-
gands (Figure 4). Another strategy to eliminate carboxylate
Table 3. Summary of ITC measurement binding parameters with errors.[a]
Ligand Kd [mm] DH [kcalmol
@1] @TDS [kcalmol@1] DG [kcalmol@1] N
1 2.3:0.9 @2.6:0.3 @4.9 @7.5 0.9
7 41:15 4.0:1.0 @9.9 @5.9 0.7
[a] Kd, DH, and N (stoichiometry) are directly measured parameters, which are determined from the fit of binding data. The error is the fitting error, so it
shows how good the fit (and corresponding binding equation) describes the experimental data. N<1 means that the real concentration of binding protein
is lower than the total protein concentration in the sample (as determined by UV spectroscopy). The Gibbs free energy and entropic contribution to bind-
ing are estimated from the following equations: DG=RTln(Kd) and DG=DH@TDS.
Table 4. Apparent in vitro potency of test compounds against isolated
KDM4A in the FDH and LANCE assays.
Ligand IC50 [mm]
FDH LANCE Ultra
6 21.8 216:33
7 28.3 195:39
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groups, different from a simple ester modification, is their re-
placement by isosteric groups. One such group is the tetrazole
moiety. Given that, it seems surprising that no such structures
of complexes have been reported for KDM4 proteins, to date,
although tetrazolylhydrazide compounds in KDM4 inhibition
were first reported in 2015 by Reger et al.[19]
Role of the hydrazide group in KDM4 inhibitors
Hydrazide-containing ligands display a bidentate coordination
of the metal ion. This is clearly evidenced by the structures of
KDM4D in complex with compounds 1 to 3 and 5 to 7. Substi-
tution of the hydrazide group in compound 4 by a simple
ethyl ester was not tolerated and resulted in a different mode
of binding of compound 4 to KDM4D with respect to the ali-
phatic part of the molecule. It seems as if the unmodified hy-
drazide is necessary for binding to the active-site metal ion,
but also for interacting with neighboring active-site residues,
Ser200 and Asn202. Among all reported structures, to date,
the nitrogen atom coordinating the metal in the same position
as that in the hydrazide ligands described herein is observed
only in daminozide, which is a compound described as a po-
tential JmjC oxygenase inhibitor (PDB ID: 4AI9).[13p] Closer in-
spection of the hydrogen-bonding interactions clearly shows
that the dimethylamino group in daminozide prevents binding
to Ser200 and Asn202 (Figure 4B). This interaction is observed
in our compounds that exhibit low micromolar affinity: com-
pounds 1 and 7. The binding potency of the hydrazide is also
shown in the case of compound 6. The benzene ring is incor-
porated between the two main functional groups of the
ligand; thus rigidifying it. Steric clashes prevent it from binding
in the same bidentate manner as that reported for other tetra-
zolylhydrazide ligands and for 2OG. Nevertheless, it is still che-
lating the metal ion by replacing the water molecule for a hy-
drazide nitrogen atom. Consequently, the hydrazide appears to
be a very powerful motif for chelating the metal ion in the
active site of KDM4 enzymes.
Tetrazole ring as a carboxyl group isostere
The second carboxyl group of the cofactor, which is distal to
the chelated metal ion, was replaced by a tetrazole ring. It was
anticipated that the tetrazole ring or its anionic counterpart,
deprotonated tetrazolate, would occupy a similar position to
that of the carboxylate group of 2OG and would thus maintain
the interactions that were reported to have a great impact on
binding affinity (Figure 4). Also, apart from the binding affinity,
the hope was that, by introducing the tetrazole group, other
properties would be introduced that would turn out to be ad-
vantageous for further development into drugs against KDM4
enzymes. Substitution of the carboxylic acid with the tetrazole
moiety should make the compounds more lipophilic, and thus,
improve cell permeability. It is clear that this notion remains
speculative, until cell penetration experiments have been per-
formed. However, it has been shown previously that this small,
nitrogen-rich functional heterocycle can serve simultaneously
as an aromatic platform and as a functional interaction
motif.[20] Tetrazoles were reported as KDM4 binders by Reger
et al. in 2015.[19] Among other reported KDM4 inhibitors, the
most similar moiety to tetrazole is a triazole, which has been
incorporated into a pyridine carboxylate scaffold. Many such
derivatives have been synthesized and tested.[13f] However,
their spatial position and orientation in the active site of the
KDM4 enzymes is very different from that observed in the li-
gands reported herein. In contrast, tetrazole rings of ligands
presented herein are never engaged in direct metal chelation,
although an indirect, water-mediated metal interaction could
be observed for compound 4. In most of the structures report-
ed herein, the tetrazole ring is sandwiched between two aro-
matic residues in the active site, Phe189 and Tyr181. This posi-
tion must be considered favorable based on the inspection of
all of the structures. A proof of concept comes from the analy-
sis of the structure of KDM4D in complex with compound 4.
Compound 4 does not have a hydrazide group chelating the
metal ion, and thus, does not bind the metal directly. This lack
of metal chelation explains why compound 4 cannot compete
efficiently with the co-substrate 2OG and does not inhibit
Figure 4. Interactions of various, previously described ligands containing car-
boxylic moieties with KDM4D (A, C) and KDM4A (B, D, E, F). Daminozide: N-
(dimethylamino)succinamic acid. Ligands are colored gray, active-site resi-
dues are colored yellow, and the metal ions are shown as green spheres.
Polar interactions are indicated as black dashed lines. The orange dashed
lines highlight aromatic stacking interactions.
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KDM4. Nevertheless, its tetrazole ring is retained in the same
position very close to those observed in the other tetrazole
compounds 1 to 4 and 6 to 7. It must therefore be concluded
that this position is favorable for an aromatic platform that is
able to engage in stacking interactions. The presence of two
aromatic systems, for example, a tetrazole and a benzene
group, for example, in compound 7 seems to increase the en-
tropic contribution of the binding in KDM4D, but not in
KDM4A. As a matter of fact, it is much higher than that in the
case of ligand 1. The position of the aromatic system, as re-
ported herein, has not been observed previously, probably be-
cause most of the previously reported KDM4 inhibitors possess
an aromatic ring as part of the metal chelating motif.
Role of the active-site residues of KDM4D
The obtained high-resolution structures allow an investigation
of the conformational changes of the amino acid residues in
the active site upon ligand binding. Amino acids Lys210,
Tyr136, Ser200, and Asn202 are all engaged in binding of the
natural cofactor, 2OG. The positions and conformations of
these residues are more or less the same in the cofactor-
bound and -free states of the enzyme. This suggests that the
active site is in a ready state to accommodate the cofactor in a
lock-and-key binding mode. The same position of these resi-
dues is also observed upon binding of compound 4 in the
distal area of the active-site cleft. In most instances, Asn202
points away from the metal center, except in the structure
with compound 6, in which the metal is chelated differently. A
superposition of KDM4D structures in complex with tetrazolyl-
hydrazides and a KDM structure in the presence of 2OG leads
one to assume that binding of the tetrazolylhydrazide to the
protein induces a restructuring of the active-site residues.
Asn202 is now in an “inward” position if the hydrazide group
chelates the metal ion in the same bidentate manner as that in
the natural cofactor binding, thanks to its internal nitrogen
atom. This suggests an induced-fit model for tetrazolylhydra-
zide binding to KDM4D. Interestingly, some of the compounds
described herein induce the movement of Tyr136, which en-
larges the binding cleft of the natural cofactor (Figure 5); thus
making room for even more ligand atoms. It could be clearly
observed in the complex structure with compound 7 that the
tetrazole ring pushes Tyr136 away from Lys210 from a distance
of 3.4 to 9.7 a. At the same time, the tetrazole establishes a
new interaction with Asn284. This residue is usually buried. It
is a bit surprising, however, because similar interactions have
been reported twice previously.[13g] They were observed in a
pyrazolopyrimidine ligand structure (PDB ID: 5KR7)[13g] and in
its unmethylated form (PDB ID: 5FJK). The ligand architecture
that triggers movement of Tyr136 was reported to be essential
for maintaining a high binding constant. However, the loss in
the enthalpy contribution of ligand 7 compared with 1 is sig-
nificant and might be due to losing the strong hydrogen bond
with the hydroxy group of Tyr136. The mapping of flexible resi-
dues in the active side of KDM4D might be helpful in a process
of rational design of higher affinity compounds.
Conclusion
By describing a series of tetrazolylhydrazide compounds and
by examining their respective binding modes to the target
protein KDM4D, we have unveiled several unique interactions
that were not observed previously and could potentially be
useful in further inhibitor optimization. The tetrazole ring ap-
pears to be a suitable replacement for carboxyl groups. Be-
cause of its unique features, it can establish both aromatic and
polar interactions. The hydrazide moiety seems to be a very
powerful motif for metal chelation in KDM4 proteins. In con-
trast to other previously described compounds that target
KDM4 proteins, the new compounds discussed herein might
display more desirable physicochemical properties. The new
scaffold fills an important gap in KDM4 inhibition and opens
up a new path to developing compounds with high affinity
and possibly increased permeability, at the same time. The tet-
razolylhydrazide scaffold also presents several possibilities for
ligand extension and branching. This would allow the creation
of a ligand that could extend into other binding sites, for in-
stance, the histone binding site, which has not yet been ex-
plored in the present series of compounds.
Experimental Section
Ligand synthesis
The synthesis of compounds 1–5 was described previously by
Reger et al.[19]
Figure 5. Surface representation of the binding pocket of ligand 7 colored
in green. The 2OG binding cleft is shown in the bottom panel and colored
in ruby. The active-site residues are shown as yellow sticks. The unique polar
interaction with Asn284 is shown as a dashed line. As a result of the move-
ment of Tyr136, the 2OG binding cleft extends.
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Protein expression and purification
cDNA encoding the catalytic domain of human KDM4D, compris-
ing residues 1–342, and KDM4A, comprising residues 1–359, was
purchased from Source Bioscience (Nottingham, UK). It was cloned
into the pQTEV expression vector, which encoded an N-terminal
hexahistidine tag. The proteins were purified by means of affinity
chromatography. The binding buffer consisted of 50 mm HEPES,
pH 7.5; 500 mm NaCl; 20 mm imidazole; and 1 mm tris(2-carboxye-
thyl)phosphine (TCEP). Protein was recovered from resins by using
elution buffer consisting of 50 mm HEPES, pH 7.5; 500 mm NaCl;
300 mm imidazole; and 1 mm TCEP. The His-tagged protein was
then processed by TEV protease to remove the N-terminal affinity
tag prior to further purification. In the final stage of purification,
the protein sample was subjected to size-exclusion chromatogra-
phy in the following buffer: 10 mm HEPES, pH 7.5; 300 mm NaCl;
5% (w/v) glycerol; and 0.5 mm TCEP.
Protein crystallization
KDM4D crystals were grown by using the sitting-drop vapor-diffu-
sion method at 291 K. The well solution consisted of 24% (w/v)
polyethylene glycol (PEG-3350), 180 mm ammonium sulfate, and
0.1m HEPES buffer at pH 7.0. The 19 mgmL@1 solution of protein
consisted of 0.5m NaCl, 5% (v/v) glycerol, 1 mm TCEP, and 10 mm
HEPES buffer at pH 7.5. A Gryphon crystallization robot (Art Rob-
bins Instruments) was used to mix 0.4 mL of well solution with an
equal volume of protein solution on a 96-well low-profile Intelli-
Plate (Art Robbins Instruments).
Data collection, processing, structure determination, and
refinement
For data collection, crystals were presoaked in well solution sup-
plemented with 10 mm NiCl2 for 10 min. Subsequently, they were
transferred to the ligand soaking solution, consisting of 100–
150 mm ligand in well solution (10–15% final DMSO concentra-
tion), and incubated from 30 min to 24 h. The crystals were then
cryoprotected by quickly immersing them in well solution comple-
mented with 20% (v/v) ethylene glycol and then flash-cooled in
liquid nitrogen.[23] XRD data were collected on beamlines BL14.1
and BL14.3 at the BESSY II electron storage ring operated by the
Helmholtz-Zentrum Berlin[24] by using a PILATUS 6M and a Rayonix
MX225 charge-coupled device (CCD) detector, respectively. The
data were integrated and scaled by using XDSAPP.[25] All relevant
data collection and processing statistics are given in Table 1. The
structures were solved by simple molecular replacement by using
a published KDM4 structure (PDB ID: 4HON[13m]) as a search model
and the program Phaser.[26] The resulting model was initially re-
fined with REFMAC and subsequently by phenix.refine.[27] Atomic
displacement parameters (ADPs) were refined anisotropically for all
protein atoms individually. The ligand occupancy values were de-
termined by means of refinement by using phenix.refine from
starting values of 0.75 in each case. The final model was obtained
after several cycles of refinement and manual adjustments by
using Coot[28] and validated. All refined coordinate sets and the
corresponding structure factor amplitudes have been deposited in
the Protein Data Bank. All refinement statistics are presented in
Table 2.
KDM4A FDH assay
The FDH-coupled demethylase activity assay was adapted from
ref. [29] and performed in a total volume of 20 mL on white Opti-
Plate-384 microtiter plates (PerkinElmer, Waltham, MA, USA) with
50 mm HEPES buffer at pH 7.50 containing 0.01% Tween-20. A so-
lution of KDM4A 1–359 (0.10 mgmL@1, 2.4 mm) was preincubated
with compound solutions of varying concentration (0–400 mm) in
DMSO at room temperature for 10 min. A substrate solution con-
taining 100 mm ascorbic acid, 10 mm FeSO4, 0.001 UmL
@1 FDH,
500 mm NAD+ , 50 mm 2OG, and 35 mm H3K9me3 substrate peptide
ARK(me3)-STGGK-NH2 (Peptide Specialty Laboratories, Heidelberg,
Germany) was added (final concentrations). The final DMSO con-
centration was 2% in all wells. The fluorescence intensity of the
product formed, NADH, was measured at lex=330 nm and lem=
460 nm on a POLARstar Optima microplate reader (BMG Labtech,
Ortenberg, Germany) immediately after addition (t=0) and after
1 h incubation on a horizontal shaker at 37 8C. Values were blank-
corrected and the difference in intensity at t=1 and 0 h was taken
as a measurement of enzyme activity. Activity, in percent, was com-
pared with that of compound-free DMSO control and no-substrate
negative control. Inhibition curves were analyzed by means of sig-
moidal curve fitting by using GraphPad Prism 4.00 and IC50 values
calculated from the fit parameters as mean: standard deviation
(SD) from two independent experiments.
KDM4A LANCE Ultra assay
The commercial antibody-based LANCE Ultra demethylase activity
assay (PerkinElmer, Waltham, MA, USA) was performed in a total
volume of 10 mL on white OptiPlate-384 microtiter plates
(PerkinElmer) with 50 mm HEPES buffer at pH 7.50 containing
0.01% Tween-20 and 0.01% BSA. A solution of 60 nm KDM4A 1–
359 was preincubated with compound solutions of varying con-
centration (0–1000 mm) in DMSO at room temperature for 10 min.
A substrate solution containing 100 mm ascorbic acid, 5 mm FeSO4,
1 mm 2OG, and 400 nm biotinylated H3K9me3 substrate peptide
ARTKQTARK(me3)-STGGKAPRKQLA-GGK(biotin) (BPS Bioscience, San
Diego, CA, USA) was added (final concentrations). The final DMSO
concentration was 5% in all wells. Plates were incubated on a hori-
zontal shaker at room temperature for 45 min. Reactions were
stopped by the addition of 10 mL of detection mix containing 2 nm
europium-labeled anti-H3K9me2 LANCE antibody (PerkinElmer),
50 nm ULight-streptavidin dye (PerkinElmer), and 1 mm EDTA in 1V
LANCE detection buffer (PerkinElmer; final concentrations). Plates
were again incubated on a horizontal shaker at room temperature
for 60 min. FRET intensity was measured on an EnVision 2102 mul-
tilabel plate reader (PerkinElmer) at lex=340 nm and lem=665 nm
with a delay of 100 ms. Values were blank-corrected and activity in
percent was compared with compound-free DMSO control and no-
enzyme negative control. Inhibition curves were analyzed by
means of sigmoidal curve fitting with GraphPad Prism 4.00 and
IC50 values calculated from the fit parameters as mean:SD from
two independent experiments.
FDH counterscreening assay
To evaluate the effect of test compounds on the FDH detection
system, a modified assay was performed. The test was performed
on white OptiPlate-384 microtiter plates (PerkinElmer, Waltham,
MA, USA) and the total test volume was 20 mL. The assay buffer
was 50 mm HEPES at pH 7.50 and 0.01% Tween-20. Formaldehyde
(40 mm) in assay buffer was preincubated for 10 min with com-
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pound solutions of varying concentration (10, 100, 400 mm) in
DMSO at room temperature. A solution containing 100 mm ascorbic
acid, 10 mm FeSO4, 0.001 UmL
@1 FDH, 500 mm NAD+ , and 50 mm
2OG was added. The final DMSO concentration was 2% in all wells.
The fluorescence intensity of the product NADH was measured at
lex=330 nm and lem=460 nm on a POLARstar Optima microplate
reader (BMG Labtech, Ortenberg, Germany) immediately after addi-
tion (t=0) and after 1 h incubation on a horizontal shaker at 37 8C.
Values were blank-corrected and the difference in intensity at t=1
and 0 h was taken as a measurement of FDH activity. The activity,
in percent, was given relative to that of the compound-free DMSO
control and no-enzyme negative control.
ITC measurements
ITC measurements on KDM4D and the respective tetrazolylhydra-
zide ligands were performed by using a MicroCal PEAQ-ITC micro-
calorimeter (Malvern Panalytical GmbH, Germany). Experiments
were performed in 10 mm HEPES buffer at pH 7.5, 0.5m NaCl, 5%
(v/v) glycerol, and 1 mm TCEP at 20 8C. The protein concentration
was determined spectrophotometrically at l=280 nm by using the
calculated molar extinction coefficient. The tetrazole ligands were
diluted 100–250 times in buffer up to the working concentration
from stock solutions in DMSO. The DMSO concentration in the re-
sulting solutions ranged from 0.4 to 1%. Solutions of KDM4D were
supplemented with the corresponding amount of DMSO to avoid
thermal effects as a result of buffer mismatch. Tetrazole ligands
were titrated in 13 or 19 small steps (2–3 mL) into a solution of pro-
tein in the calorimeter cell. Other experimental settings included a
spacing time of 180 s and a filtering period of 5 s. For each ligand,
all measurements were performed two or three times. For all ex-
periments, the instrument software (MicroCal PEAQ-ITC Analysis)
was used for baseline adjustment, peak integration, and normaliza-
tion of the reaction heats, with respect to the molar amount of in-
jected ligand, as well as for data fitting and binding parameter
evaluation. The thermodynamic parameters for ligands showing
measurable heat signals are presented in Table 3.
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